Biogen

Youtube Subscribe

Open: 247.22 Close: 246.21 Change: -1.01

The 10 top things that an AI found about Biogen Company Inc Stock and you do not know…

How much time have you spent trying to decide whether investing in Biogen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, stock, …

Concept Map

Semantic Network

Stock Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, AVonEX, PLE.

Today's Summary

Biogen stock slips as ubs downgrades (nasdaq:biib) | seeking alpha. biogen stock slip as uBS downgrades. Biogen slips as UBS cuts to Neutral on Alzheimers.

Today's News

Biogen stock slips as ubs downgrades (nasdaq:biib) | seeking alpha. biogen stock slip as uBS downgrades. Biogen slips as UBS cuts to Neutral on Alzheimers. Biogen Inc. (BIIB) Reports Mixed Q3 2023 Results and Revises Full-Year Guidance. Biogen to Report Q3 Earnings Wednesday. UBS downgrades Biogen (BIIB) from Buy to Neutral. Analyst price target for Biogen is 324.29 - 31.21% Upside. Microsoft closes above $3 trillion market value for first time. Biogen gets final ok for $9.75 million 401(k) fee settlement. Deal includes pledge by Biogen to improve plan management. Deal is slated to benefit about 12,000 people covered by the Biogen 401(K) plan. Research analysts expect Biogen to post 14.96 earnings per share for the current fiscal year. Biogen had a net margin of 14.63% and a return on equity of 16.40% Biogen revenue for the quarter was up.9%. On Friday, the FDA approved Biogen s Tofidence as the first biosimilar to Roches Actemra (tocilizumab) in the U.S. “immediately” The depression treatment space has had a landmark year. The current Biogen [ BIIB ] share price is $247.04 USD today. Over the next 52 weeks, Biogen has on average historically risen by 46.8% based on the past 32 years of stock performance. Head of Small Molecule and ASO Engineering at Biogen leads the Biogen Small Molecules and AsO Engineering Technical Authority function. The role is accountable for engineering subject matter expertise in small molecule and antisense oligonucleotide (ASO) modalities. Biogen has an Altman Z-Score of 3.11 and a Piotroski F-Scoring of 3. The average price target for Biogen is $322.38, which is 30.94% higher.

Stock Profile

"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts."

Keywords

This document will help you to evaluate Biogen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, stock, slip, downgrade, BIIB, price, year, and the most common words in the summary are: biogen, stock, market, biib, buy, bloomberg, top, . One of the sentences in the summary was: Biogen stock slips as ubs downgrades (nasdaq:biib) | seeking alpha. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biogen #stock #market #biib #buy #bloomberg #top.

Read more →

Youtube Subscribe

---